Adult

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

Retrieved on: 
Monday, October 16, 2023
IPD, Visp, Public, Genetically modified bacteria, PCV, SAN, Pharmaceutical industry, Fine chemical, Adult

SAN CARLOS, Calif. and BASEL, Switzerland, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, and Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced the companies have entered into a new commercial manufacturing agreement. Expanding on their existing collaboration, this agreement supports the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in both the adult and pediatric populations. This agreement complements Vaxcyte’s plans to utilize existing Lonza infrastructure to advance clinical development and the anticipated initial U.S. launch of VAX-24 for the adult population.

Key Points: 
  • Expanding on their existing collaboration, this agreement supports the potential global commercialization of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, in both the adult and pediatric populations.
  • This agreement complements Vaxcyte’s plans to utilize existing Lonza infrastructure to advance clinical development and the anticipated initial U.S. launch of VAX-24 for the adult population.
  • The design of the dedicated manufacturing suite is nearly complete, with equipment installation expected to begin in 2024.
  • “Our expanded relationship with Vaxcyte highlights the value of our services on the path towards commercialization,” said Jean-Christophe Hyvert, President, Biologics Division at Lonza.

InsightRX to Present Multiple Studies Demonstrating Advances in Precision Medicine at IDWeek 2023

Retrieved on: 
Wednesday, October 4, 2023
Vancomycin, BCPS, Nephrotoxicity, Doctor of Pharmacy, Use, Body mass index, Data science, Infection, Research, Pharmacokinetics, Acute kidney injury, Doctor of Philosophy, Aminoglycoside, Hospital, Patient safety, SAN, Medicine, Software, Pharmaceutical industry, Nursing, Adult, Patient

SAN FRANCISCO, Oct. 4, 2023 /PRNewswire/ -- InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – today announced that results of several studies analyzing the use of its software for model-informed precision dosing (MIPD) will be presented at IDWeek 2023, October 11-15 in Boston. Three distinct studies aim to spotlight data and analysis of antibiotic therapeutic drug monitoring, highlighting the potential for precision medicine enabled by InsightRX solutions to improve patient safety, enhance clinical practice, and reduce the cost of care. 

Key Points: 
  • Three distinct studies aim to spotlight data and analysis of antibiotic therapeutic drug monitoring, highlighting the potential for precision medicine enabled by InsightRX solutions to improve patient safety, enhance clinical practice, and reduce the cost of care.
  • Highly effective antibiotics, such as aminoglycosides and vancomycin, are widely used in hospitals to treat infections, yet they present unique dosing and monitoring challenges for clinicians.
  • "We're thrilled to share our latest research in model-informed precision dosing at IDWeek," said Sirj Goswami, PhD, CEO and cofounder of InsightRX.
  • poster session presented by Jonathan Faldasz, PharmD, BCPS, and Jasmine Hughes, PhD, Director of Data Science, InsightRX.

CHOP Researchers Develop Novel Method Using MRI to Study Diseases Modeled in Zebrafish

Retrieved on: 
Wednesday, September 20, 2023
Online, Zebrafish, SURF1, Tissue, Heart, Human, Magnetic resonance, CHOP, Life, Spinal cord, Research, Cell, Fertilisation, Bangladesh Technical Education Board, MRI, Genetics, Magnetic resonance imaging, Animal, HIV disease progression rates, MD, Patient, Division, Leigh syndrome, Neurology, Cardiomyopathy, Hospital, Mitochondrial disease, Atlas, New York State Division of Human Rights, Gene, Skin, Disease, Children's Hospital of Philadelphia, Vaccine, Medical imaging, Adult

PHILADELPHIA, Sept. 20, 2023 /PRNewswire/ -- Zebrafish have revolutionized research into a wide variety of rare and complex genetic diseases. In early development stages, their transparent bodies allow researchers to more easily study tissues and organs. However, studying organ-level defects in adult zebrafish presents a variety of challenges that prevent researchers from studying them at a microscopic level.

Key Points: 
  • In a new study, researchers from Children's Hospital of Philadelphia (CHOP) have developed a noninvasive method for conducting magnetic resonance imaging (MRI) in adult zebrafish.
  • In addition, zebrafish are often used to create models to study diseases because zebrafish share about 70% of genes found in humans.
  • While MRI has been used to study zebrafish, prior studies have been very limited and did not provide systematic organ-level analyses.
  • Zebrafish.

Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs

Retrieved on: 
Friday, September 8, 2023
Xenon, Risk, Partnership, Radiation, Inhalation, Transience, AIM, Doctor of Philosophy, Supplement, Clinical trial, Hypoesthesia, Research, Biomarker, VIDA, MRI, Magnetic resonance imaging, Dizziness, Severe cutaneous adverse reactions, Oxygen saturation (medicine), Patient, Acquisition, Physician, Algorithm, Euphoria, Ageing, Hypoxemia, Heart rate, Headache, Adolescence, Medical imaging, Adult

The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.

Key Points: 
  • The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
  • “Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW™ MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
    “VIDA and Polarean are natural partners.
  • Since the technology is based on MRI, it does not expose patients to any ionizing radiation and its associated risks.
  • The dose of XENOVIEW, created through the Polarean HPX hyperpolarization system, is administered in a single 10-15 second breath-hold MRI procedure.

Tim Dunnigan Joins Draganfly Advisory Board Helping Spearhead Pentagon Replicator Program Initiatives

Retrieved on: 
Thursday, September 7, 2023
AT&T, Pentagon, Bachelor, 2019 iK9 Service Dog 200, SDVOSB, CSE, Education, Doctor of Philosophy, AT, United States Department of Defense, Replicator, Create, System, Veteran, FSE, Research, Ericsson, Auburn University, American Service-Members' Protection Act, Aflac, Entrepreneurship, United States Department of the Army, Cox Communications, Leadership studies, Master, Human development, Verizon Communications, Master's degree, T-Mobile, PTSD, Management, Adult

Los Angeles, CA., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that Tim Dunnigan has been appointed to Draganfly’s Advisory Board to help lead Company’s initiatives for the new Pentagon Replicator program.

Key Points: 
  • Los Angeles, CA., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions, and systems developer, is pleased to announce that Tim Dunnigan has been appointed to Draganfly’s Advisory Board to help lead Company’s initiatives for the new Pentagon Replicator program.
  • This initiative stands to benefit Draganfly through increased demand, expanded business prospects, potential technology advancements, research and development collaboration, global recognition, and economic growth.
  • "I'm excited to be appointed as an advisor on this new initiative, and to contribute to Draganfly's role in shaping the future of defense and national security," remarked Tim Dunnigan.
  • "We are also excited to welcome Tim Dunnigan as Draganfly’s Advisor to help spearhead the newly launched Pentagon Replicator Program," said Cameron Chell, President, and CEO of Draganfly.

Zimmer Biomet Announces Key Updates to Company's Executive Leadership Team

Retrieved on: 
Tuesday, September 5, 2023
Pennsylvania State University, Bachelor's degree, Medicine, Bachelor, UnitedHealth Group, Hip, University, Senior, Marketing, Erasmus University Rotterdam, Business economics, Business, MBA, Innovation, Thomas Jefferson University, Economics, Strategic leadership, Medtronic, University of Richmond, Acquisition, Novartis, Patient, Thomas Jefferson University Hospital, Region, Chief innovation officer, Michelin, Teleflex, Orthopedic surgery, NYSE, Zuilen, Covidien, Management, Virginia Tech, Adult, Optum

WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team. Wilfred van Zuilen has been promoted to Group President, EMEA; Mark Bezjak was promoted to President of the Americas; and Chief Science, Technology and Innovation Officer Nitin Goyal, M.D. has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.

Key Points: 
  • Appointed to Executive Leadership Team
    WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team.
  • has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.
  • "The expansion of Zimmer Biomet's Executive Leadership Team coincides with our renewed focus on commercial execution and innovation to drive the Company forward," said Mr. Tornos.
  • Wilfred Van Zuilen Promotion to Group President, EMEA
    Mr. van Zuilen joined Zimmer Biomet in June 2021 as President, EMEA.

EmergeOrtho-Triangle Region Welcomes Dr. Rhett Hallows, Joint Replacement Surgeon

Retrieved on: 
Monday, August 28, 2023
Bachelor of Science, University, Hip, University of Utah School of Medicine, ABMS, Elective surgery, Arthroplasty, Wilson, Triangle, MD, Patient, Wake Forest, Faculty, Health, Knee, Injury, Medical device, Nursing, Southern Utah University, Science, Adult

DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- Dr. Rhett Hallows, a renowned Joint Replacement Specialist joins EmergeOrtho-Triangle Region's team of orthopedic surgeons, with a focus on the anterior-based muscle-sparing (ABMS) hip replacement approach.

Key Points: 
  • DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- Dr. Rhett Hallows, a renowned Joint Replacement Specialist joins EmergeOrtho-Triangle Region's team of orthopedic surgeons, with a focus on the anterior-based muscle-sparing (ABMS) hip replacement approach.
  • Dr. Hallows has also become proficient in the ABMS approach to hip replacement, which offers a rapid hip replacement recovery, similar to anterior total hip arthroplasty.
  • "Having Dr. Rhett Hallows on our team is truly a privilege," Medical Director of EmergeOrtho-Triangle Region, Dr. Will Silver said.
  • Since 1952, EmergeOrtho–Triangle Region has been providing comprehensive subspecialty orthopedic care to address a diverse variety of injuries and conditions.

Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, August 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Columbia University, PD, Senior, Investment, Cohort, DHEAS, CAH, Clinical trial, Infection, Spruce, Pharmacokinetics, Public, Woman, G&A, Polycystic ovary syndrome, POWER, Public expenditure, Public health, Adrenal insufficiency, A4, Polycystic disease, Patient, PCOS, Administration, Adolescence, Androstenedione, Financial toxicity, Regulatory affairs, Research and development, Regulation, R, FDA, Safety, Dehydroepiandrosterone sulfate, Pharmaceutical industry, Nursing, Cryptocurrency, Adult, Quality

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
  • In our CAHmelia program in adult classic CAH, we’ve surpassed 75% enrollment in the CAHmelia-203 study and are approaching 75% enrollment in the CAHmelia-204 study.
  • Cohort 2 in our CAHptain study for pediatric classic CAH is nearly fully enrolled, with screening in cohort 3 currently underway.
  • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2023 were $120.5 million.

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

Retrieved on: 
Monday, July 31, 2023
KOL, MGH, Metabolism, Pituitary gland, Sequoyah, Clinical trial, Saint Andrew's Society, Medicine, Research, BSN, Harvard Medical School, Acromegaly, American Association of Clinical Endocrinologists, Patient, SAN, European Society of Endocrinology, Endocrine Society, Diagnosis, Hospital, Massachusetts General Hospital, Pharmaceutical industry, Adult, Endocrinology

(Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.

Key Points: 
  • (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.
  • and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs).
  • Karen JP Liebert, R.N., B.S.N., is a research nurse / study coordinator in the Neuroendocrine Department at Massachusetts General Hospital (MGH).
  • She is a member of the Endocrine Nursing Society and has co-authored numerous peer-reviewed publications.

Global $30+ Billion Orthodontics Market to 2030: Overcoming Challenges with Opportunities Across Clear Braces, Fixed Braces, Bonding, Adhesives, Springs, Tubes, & Bands - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Dental, Health, Dentistry, Prevalence, Nickel, Orthodontics, Adhesive, Malocclusion, Titanium, Bruxism, Hospital, Adolescence, Brace, Dental care, Clifton Springs Hospital & Clinic, Growth, Bracket, Adult, Research

The global orthodontics market is projected to reach $30.2 billion by 2030, at a CAGR of 14.6% from 2023 to 2030.

Key Points: 
  • The global orthodontics market is projected to reach $30.2 billion by 2030, at a CAGR of 14.6% from 2023 to 2030.
  • The growing demand for orthodontic treatments in emerging countries is expected to generate growth opportunities for the players operating in this market.
  • However, the lack of skilled professionals and low awareness regarding orthodontic treatments are challenges for the players operating in this market.
  • Based on product, in 2023, the removable braces segment is expected to account for the largest share of the orthodontics market.